Precision BioSciences Inc. (DTIL)
NASDAQ: DTILHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DTIL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $282.46M
- P/E (TTM)
- 29.60
- EPS (TTM)
- $0.25
- Dividend yield
- None
- 52-week range
- 3.53 – 11.29
- Day range
- 6.77 – 7.55
- Volume / Avg
- 429.79K / 319.79K
- Beta
- —
- Shares outstanding
- 38.17M
52-week range
DTIL stock today
Shares of Precision BioSciences (DTIL) finished higher on Nov 20 at $7.40, a gain of 7.09% or $0.49 per share, versus the S&P 500's 3.70% decline. Shares are 34.5% below their 52-week high of $11.29, set on Nov 5, 2026 and 109.6% above the 52-week low of $3.53, in the middle of the past year's range. DTIL is up 77.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 48.0%.
Precision BioSciences trades at 29.6x its trailing twelve-month earnings per share of $0.25.
Summary generated from market data by MetaCap's automated system. Methodology
About Precision BioSciences
Company profilePrecision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Michael Amoroso
- Headquarters
- Durham, NC
- Employees
- 69
- IPO year
- 2019
- Website
- precisionbiosciences.com
Financial highlights
Full financialsIn fiscal 2025, Precision BioSciences generated $34.3 million in revenue, down 50.1% from fiscal 2024, its first annual decline since 2022. Precision BioSciences reported a net loss of $45.7 million, compared with net income of $7.2 million a year earlier. Operating margin was -152.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $34.26M | $68.70M | $48.73M | $25.10M | $115.53M |
| Growth | -50.12% | +40.98% | +94.15% | -78.28% | +375.72% |
| Net income | $-45.72M | $7.17M | $-61.32M | $-111.64M | $-30.60M |
| EPS (diluted) | $-3.56 | $1.04 | $-15.96 | $-38.10 | $-0.52 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$29.40+297.30%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-1.84 vs $-1.02
- Surprise
- -80.39%
DTIL news
All DTIL news- Precision BioSciences, Inc. Projects Cash Runway into Fourth Quarter of 2029Nasdaq
- Precision BioSciences, Inc. Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNasdaq
- Precision BioSciences, Inc. Reports Third Quarter 2026 Financial ResultsNasdaq
- Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire
- Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026Business Wire
Precision BioSciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AGENAgenus Inc. | 5.97 | -2.77% | $270.12M | vs DTIL |
| KYTXKyverna Therapeutics Inc. | 4.26 | -2.52% | $269.33M | vs DTIL |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs DTIL |
| TRXBTRex Bio Inc. | 10.32 | +6.12% | $296.95M | vs DTIL |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs DTIL |
| XFORX4 Pharmaceuticals Inc. | 3.00 | +1.35% | $306.34M | vs DTIL |
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs DTIL |
| SLBTSL Science Holding Limited | 0.55 | -3.36% | $308.42M | vs DTIL |
Indexes, lists and sector
Precision BioSciences stock FAQ
What is Precision BioSciences's stock price today?
DTIL last traded at $7.40 as of Nov 20, 4:00 PM EST, up 7.09% on the day. Prices are delayed at least 15 minutes.
Does Precision BioSciences pay a dividend?
No. Precision BioSciences does not currently pay a regular cash dividend.
What is DTIL's P/E ratio?
DTIL trades at a trailing P/E ratio of 29.60.
Who is Precision BioSciences's CEO?
Mr. Michael Amoroso is the chief executive officer of Precision BioSciences Inc., which has about 69 employees.
Has DTIL ever split its stock?
Yes. The most recent DTIL stock split was a 1-for-30 split on Feb 14, 2024.
What is the DTIL 52-week high?
The 52-week high for DTIL is $11.29 and the 52-week low is $3.53. The stock is currently 34.5% below its high.